BioSpace News Archive

The partnership with Chinese biotech Cellular Biomedicine Group will cost J&J $245 million upfront and give it access to two differentiated CAR-T therapies for diffuse large B-cell lymphoma.

For $150 million upfront, Sanofi will gain access to Maze’s lead asset MZE001, which inhibits the GYS1 protein in the rare genetic disorder.

Scientists must act differently than other professionals to build a successful personal brand on social media. Check out our comprehensive guide to get started.

In addition to promoting their brands, companies say their funding initiatives give them access to the expertise of top researchers and contribute to society.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced first quarter results.

AmerisourceBergen Corporation reported that in its fiscal year 2023 second quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion.

Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced several presentations during the 2023 American Society of Cataract and Refractive Surgery Annual Meeting to be held May 5-8, 2023 in San Diego, California.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 , at 1:40 p.m. PDT.

Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2023 and reaffirmed full-year 2023 financial guidance.

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.